Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders' Equity

v3.21.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Balance at beginning of period at Dec. 31, 2019 $ 186,348 $ 7 $ 812,133 $ 80 $ (625,872)
Balance at beginning of period (in shares) at Dec. 31, 2019   68,882,459      
Stock-based compensation expense 1,998   1,998    
Net loss (13,088)       (13,088)
Net unrealized gain on marketable securities (210)     (210)  
Balance at end of period at Mar. 31, 2020 175,048 $ 7 814,131 (130) (638,960)
Balance at end of period (in shares) at Mar. 31, 2020   68,882,459      
Balance at beginning of period at Dec. 31, 2019 186,348 $ 7 812,133 80 (625,872)
Balance at beginning of period (in shares) at Dec. 31, 2019   68,882,459      
Net loss (35,235)        
Net unrealized gain on marketable securities 2        
Balance at end of period at Sep. 30, 2020 156,635 $ 7 817,653 82 (661,107)
Balance at end of period (in shares) at Sep. 30, 2020   68,887,092      
Balance at beginning of period at Mar. 31, 2020 175,048 $ 7 814,131 (130) (638,960)
Balance at beginning of period (in shares) at Mar. 31, 2020   68,882,459      
Issuance of common stock upon exercise of stock options, value 7   7    
Issuance of common stock upon exercise of stock options, (Shares)   4,633      
Stock-based compensation expense 963   963    
Net loss (10,726)       (10,726)
Net unrealized gain on marketable securities 316     316  
Balance at end of period at Jun. 30, 2020 165,608 $ 7 815,101 186 (649,686)
Balance at end of period (in shares) at Jun. 30, 2020   68,887,092      
Stock-based compensation expense 2,552   2,552    
Net loss (11,421)       (11,421)
Net unrealized gain on marketable securities (104)     (104)  
Balance at end of period at Sep. 30, 2020 156,635 $ 7 817,653 82 (661,107)
Balance at end of period (in shares) at Sep. 30, 2020   68,887,092      
Balance at beginning of period at Dec. 31, 2020 142,706 $ 7 819,549 8 (676,858)
Balance at beginning of period (in shares) at Dec. 31, 2020   68,946,092      
Stock-based compensation expense 2,505   2,505    
Net loss (17,551)       (17,551)
Net unrealized gain on marketable securities (14)     (14)  
Balance at end of period at Mar. 31, 2021 127,646 $ 7 822,054 (6) (694,409)
Balance at end of period (in shares) at Mar. 31, 2021   68,946,092      
Balance at beginning of period at Dec. 31, 2020 142,706 $ 7 819,549 8 (676,858)
Balance at beginning of period (in shares) at Dec. 31, 2020   68,946,092      
Net loss (63,455)        
Net unrealized gain on marketable securities (9)        
Balance at end of period at Sep. 30, 2021 87,058 $ 7 827,365 (1) (740,313)
Balance at end of period (in shares) at Sep. 30, 2021   69,043,969      
Balance at beginning of period at Mar. 31, 2021 127,646 $ 7 822,054 (6) (694,409)
Balance at beginning of period (in shares) at Mar. 31, 2021   68,946,092      
Issuance of common stock upon exercise of stock options, value 106   106    
Issuance of common stock upon exercise of stock options, (Shares)   51,846      
Stock-based compensation expense 2,557   2,557    
Net loss (23,222)       (23,222)
Net unrealized gain on marketable securities 7     7  
Balance at end of period at Jun. 30, 2021 107,094 $ 7 824,717 1 (717,631)
Balance at end of period (in shares) at Jun. 30, 2021   68,997,938      
Issuance of common stock upon exercise of stock options, value 99   99    
Issuance of common stock upon exercise of stock options, (Shares)   46,031      
Stock-based compensation expense 2,549   2,549    
Net loss (22,682)       (22,682)
Net unrealized gain on marketable securities (2)     (2)  
Balance at end of period at Sep. 30, 2021 $ 87,058 $ 7 $ 827,365 $ (1) $ (740,313)
Balance at end of period (in shares) at Sep. 30, 2021   69,043,969